PTCT - PTC Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
33.63
-0.13 (-0.39%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close33.76
Open33.59
Bid0.00 x 1800
Ask0.00 x 800
Day's Range33.51 - 34.90
52 Week Range15.97 - 52.95
Volume367,643
Avg. Volume783,389
Market Cap1.697B
Beta (3Y Monthly)3.24
PE Ratio (TTM)N/A
EPS (TTM)-1.77
Earnings DateMar 4, 2019 - Mar 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est50.71
Trade prices are not sourced from all markets
  • Simply Wall St.4 days ago

    Is PTC Therapeutics, Inc.’s (NASDAQ:PTCT) CEO Paid Enough Relative To Peers?

    Stuart Peltz became the CEO of PTC Therapeutics, Inc. (NASDAQ:PTCT) in 1998. First, this article will compare CEO compensation with compensation at similar sized companies. Then we'll look at a Read More...

  • Ghost Tree Capital’s AUM, Returns and Holdings
    Insider Monkey4 days ago

    Ghost Tree Capital’s AUM, Returns and Holdings

    David Kim’s Ghost Tree Capital is a health-care oriented hedge fund with a headquarter in New York. It was founded five years ago, back in 2013, by Ken Greenberg, Matt Diaz (Trader), Brian Kim (Senior Analysts), and of course David Kim. This large advisory firm provides portfolio management services for pooled investment vehicles and pension funds. David […]

  • Hedge Funds Are Buying PTC Therapeutics, Inc. (PTCT)
    Insider Monkey6 days ago

    Hedge Funds Are Buying PTC Therapeutics, Inc. (PTCT)

    How do you pick the next stock to invest in? One way would be to spend hours of research browsing through thousands of publicly traded companies. However, an easier way is to look at the stocks that smart money investors are collectively bullish on. Hedge funds and other institutional investors usually invest large amounts of […]

  • PR Newswire9 days ago

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Dec. 7, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on December 4, 2018 it approved non-statutory stock options to purchase an aggregate of 48,750 shares of its common stock to 10 new employees.  The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on December 4, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). All stock option awards have an exercise price of $34.35 per share, the closing price of PTC's common stock on December 4, 2018, the date of the grant.  The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the Company through the applicable vesting dates.

  • GlobeNewswire17 days ago

    Report: Exploring Fundamental Drivers Behind J.B. Hunt Transport Services, Kura Oncology, National Beverage, Benefitfocus, PTC Therapeutics, and Walgreens Boots Alliance — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents26 days ago

    Edited Transcript of PTCT earnings conference call or presentation 5-Nov-18 9:30pm GMT

    Q3 2018 PTC Therapeutics Inc Earnings Call

  • PR Newswirelast month

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Nov. 16, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on November 13, 2018 it approved non-statutory stock options to purchase an aggregate of 75,200 shares of its common stock to 19 new employees.  The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on November 13, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). Fifteen of the stock option awards have an exercise price of $31.96 per share, the closing price of PTC's common stock on November 13, 2018, the date of the grant.

  • New Strong Sell Stocks for November 9th
    Zackslast month

    New Strong Sell Stocks for November 9th

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

  • Here's Why PTC Therapeutics Dropped 18% in October
    Motley Foollast month

    Here's Why PTC Therapeutics Dropped 18% in October

    The company's development-stage SMA treatment was supposed to knock out the market leader, but now it may be the one at risk of an upset.

  • PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates
    Zackslast month

    PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates

    PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -135.00% and -21.87%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    PTC Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the South Plainfield, New Jersey-based company said it had a loss of $1.06. Losses, adjusted for asset impairment costs, came to 94 cents per share. The biopharmaceutical company ...

  • Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending
    Insider Monkeylast month

    Amazon, Pandora, PTC Therapeutics, and More: Why These Stocks Are Trending

    Although November 6 is very important to the stock market because it’s election day in the United States, traders are also paying attention to several equities that are trending for various reasons. Without further elaboration, let’s dive in and see why the spotlight is shining on Amazon.com Inc. (NASDAQ:AMZN), The Kraft Heinz Company (NASDAQ:KHC),  Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), PTC […]

  • PR Newswirelast month

    PTC Therapeutics Reports Third Quarter 2018 Financial Results and Provides a Corporate Update

    -Completed acquisition of Agilis Biotherapeutics gene therapy platform- -In-licensed two rare disease therapies from Akcea Therapeutics- SOUTH PLAINFIELD, N.J. , Nov. 5, 2018 /PRNewswire/ -- PTC Therapeutics, ...

  • PR Newswire2 months ago

    PTC Therapeutics to Participate at Upcoming Investor Conference

    SOUTH PLAINFIELD, N.J. , Oct. 30, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Credit Suisse 27 th Annual Healthcare ...

  • PTC Therapeutics (PTCT) Q3 Earnings Preview: What to Watch Ahead of the Release
    Zacks2 months ago

    PTC Therapeutics (PTCT) Q3 Earnings Preview: What to Watch Ahead of the Release

    PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Simply Wall St.2 months ago

    How Does PTC Therapeutics Inc (NASDAQ:PTCT) Affect Your Portfolio Volatility?

    Anyone researching PTC Therapeutics Inc (NASDAQ:PTCT) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Read More...

  • PR Newswire2 months ago

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Oct. 23, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on October 17, 2018 it approved non-statutory stock options to purchase an aggregate of 68,700 shares of its common stock to 13 new employees.  The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on October 17, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). Eight of the stock option awards have an exercise price of $39.73 per share, the closing price of PTC's common stock on October 17, 2018, the date of the grant.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in PTC Therapeutics, AeroVironment, Autodesk, Coca-Cola Bottling Co. Consolidated, Akers Biosciences, and TEGNA — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • PR Newswire2 months ago

    PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2018 Financial Results

    SOUTH PLAINFIELD, N.J. , Oct. 22, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2018 financial ...

  • PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation
    PR Newswire2 months ago

    PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna™ (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation

    SOUTH PLAINFIELD, N.J., Oct. 6, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced preliminary data from the first international drug registry for Duchenne patients receiving Translarna™ (ataluren), underscoring the long-term clinical benefit of Translarna when used in routine clinical practice in delaying irreversible muscle loss in children with Duchenne caused by a nonsense mutation, when compared with published natural history. The data show that children and adolescents receiving Translarna in the real-world setting are continuing to walk years longer than untreated children, and are staying more physically able.

  • PR Newswire2 months ago

    Risdiplam Demonstrates Preliminary Evidence of Clinical Benefit in Type 1, 2, & 3 Spinal Muscular Atrophy Patients

    - Babies from FIREFISH Part 1 study showed increased survival & gains in developmental milestones - - SUNFISH Part 1 study demonstrated a 3.1-point increase in motor function as measured by MFM32 - - Pivotal ...

  • PR Newswire3 months ago

    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SOUTH PLAINFIELD, N.J., Sept. 28, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) today announced that on September 25, 2018 it approved non-statutory stock options to purchase an aggregate of 122,200 shares of its common stock to 33 new employees.  The awards were made pursuant to the NASDAQ inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on September 25, 2018 and are being made as an inducement material to each employee's acceptance of employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).

  • PR Newswire3 months ago

    PTC Therapeutics to Participate at Upcoming Investor Conference

    SOUTH PLAINFIELD, N.J. , Sept. 25, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Chardan Genetic Medicines Conference on Tuesday, ...

  • Do Options Traders Know Something About PTC Therapeutics (PTCT) Stock We Don't?
    Zacks3 months ago

    Do Options Traders Know Something About PTC Therapeutics (PTCT) Stock We Don't?

    Investors need to pay close attention to PTC Therapeutics (PTCT) stock based on the movements in the options market lately.

  • How’s PTC Therapeutics Positioned in September?
    Market Realist3 months ago

    How’s PTC Therapeutics Positioned in September?

    In the second quarter, PTC Therapeutics generated revenues of $68.7 million—compared to $48.0 million in the second quarter of 2017, which reflected ~43% growth YoY (year-over-year). In the first half of 2018, PTC Therapeutics reported net revenues of $124.8 million—compared to $74.5 million in the first half of 2017.